References
- Sokal J E, Cox E B, Baccarani M, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 1984; 63: 789–799
- Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon α. J Natl Cancer Inst 1998; 90: 850–858
- Hughes T. ABL kinase inhibitor therapy for CML: baseline assessments and response monitoring. Am Soc Hematol 2006; 211–218
- Duque R E, Andreeff M, Braylan R C, Diamond L W, Peiper S C. Consensus review of the clinical utility of DNA flow cytometry in neoplastic hematopathology. Cytometry 1993; 14: 492–496
- Clark G M, Mathieu M C, Owens M A, et al. Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. J Clin Oncol 1992; 10: 428–432
- Tripathi A K, Chaturvedi R, Ahmad R, et al. Flow cytometric analysis of S-phase fraction and aneuploidy in chronic myeloid leukemia patients: role in early detection of accelerated phase. Leuk Res 2003; 27: 899–902
- Issaad C, Ahmed M, Novault S, et al. Biological effects induced by variable levels of BCR-ABL protein in pluripotent hematopoietic cell line UT-7. Leukemia 2000; 14: 662–670
- Sawyers C L. Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330–1339
- Cancer therapy evaluation program. Common toxicity criteria version 3.0. National Cancer Institute, National Institute of Health Publication Handy Dex LLC, United States 2006
- Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645–652
- Krishnan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 1975; 66: 188–193
- Deshmukh C, Saikia T, Bakshi A, Amare-Kadam P, Baisane C, Parikh P. Imatinib mesylate in chronic myeloid leukemia: a prospective, single arm, non-randomized study. J Assoc Physicians India 2005; 53: 291–295
- Jorgensen H G, Copland M, Holyoake T L. Granulocyte–colony stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia. Cancer 2005; 103: 210–211
- Sneed T B, Kantarjian H M, Talpaz M, et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer 2004; 100: 116–121
- Jiang Q, Chen S, Jiang B, et al. [Relationship between cytopenia and cytogenetic response in imatinib mesylate treated Ph-positive chronic myeloid leukemia in chronic phase patients]. Beijing Da Xue Xue Bao 2003; 35: 136–140